checkAd

     149  0 Kommentare Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS (opicapone) - Seite 2

    “We are fully committed to creating value for people living with severe neurological conditions worldwide, being the U.S. is a key geography for BIAL. Amneal shares our long-term vision for ONGENTYS, and our partnership will allow us to expand its accessibility, continuing to make a difference for patients suffering from Parkinson’s disease in the U.S.,” said Max Bricchi, Executive Vice President, Chief Commercial Officer of BIAL.

    The financial terms of the agreement were not disclosed, and any incremental expenses associated with this product are contemplated within Amneal’s guidance.

    Important Information

    Approved Use
    ONGENTYS (opicapone) capsules is a prescription medicine used with levodopa and carbidopa in people with Parkinson's disease (PD) who are having "OFF" episodes.
    It is not known if ONGENTYS is safe and effective in children.

    Important Safety Information

    Do not take ONGENTYS if you:

    • take a type of medicine called a non-selective monoamine-oxidase (MAO) inhibitor.
    • have a tumor that secretes hormones known as catecholamines.

    Before taking ONGENTYS, tell your healthcare provider about all of your medical conditions, including if you:

    • have daytime sleepiness from a sleep disorder, have unexpected periods of sleep or sleepiness, or take a medicine to help you sleep or that makes you feel sleepy.
    • have had intense urges or unusual behaviors, including gambling, increased sex drive, binge eating, or compulsive shopping.
    • have a history of uncontrolled sudden movements (dyskinesia).
    • have had hallucinations or psychosis.
    • have liver or kidney problems.
    • are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.

    Lesen Sie auch

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take nonselective MAO inhibitors (such as phenelzine, tranylcypromine, and isocarboxazid) or catecholamine medicines (such as isoproterenol, epinephrine, norepinephrine, dopamine, and dobutamine), regardless of how you take the medicine (by mouth, inhaled, or by injection).

    Seite 2 von 6



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS (opicapone) - Seite 2 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS (opicapone) in the U.S. starting on …